

Contents

*List of Contributors*   xi  
*Foreword*   xix  
*Acknowledgments*   xx

Section 1: Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem

1 **Alzheimer’s Disease Drug Development: A Research and Development Ecosystem**   1  
Jeffrey Cummings, Jefferson Kinney, and Howard Fillit

2 **Drug Development for Alzheimer’s Disease: An Historical Perspective**   25  
Howard Fillit and Jeffrey Cummings

3 **Alzheimer’s Disease Drug Discovery in Academia: From High-Throughput Screening to In Vivo Testing**   34  
Kurt R. Brunden, Goodwell Nzou, and Carlo Ballatore

4 **The Harrington Discovery Institute and Alzheimer’s Disease Drug Development**   45  
Andrew A. Pieper, J. Simon Mazza-Lunn, and Diana R. Wetmore

5 **Repurposed Agents in Alzheimer’s Disease Drug Development**   54  
Clive Ballard and Janet Sultana

6 **Artificial Intelligence in Alzheimer’s Drug Discovery**   62  
Feixiong Cheng and Jeffrey Cummings

Section 2: Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs

7 **Role of Animal Models in Alzheimer’s Disease Drug Development**   73

Jefferson Kinney, Amanda M. Leisgang Osse, Bruce Lamb, Adrian Oblack, Alan D. Palkowitz, and Frank J. Belas, Jr.

8 **Use of Induced Pluripotent Stem Cell-Derived Neuronal Disease Models from Patients with Familial Early-Onset Alzheimer’s Disease in Drug Discovery**   95  
Brenda Hug, Rudolph E. Tanzi, and Steven L. Wagner

9 **Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer’s Disease Drug Discovery**   106  
Min Su Kang, Eduardo R. Zimmer, Julie Ottoy, Monica Shin, Marcel Seungsu Woo, Arturo Aliaga, Gassan Massarweh, A. Claudio Cuello, Serge Gauthier, and Pedro Rosa-Neto

10 **Biobanking and Biomarkers in the Alzheimer’s Disease Drug-Development Ecosystem**   123  
Jefferson Kinney and Arnold Salazar

Section 3: Alzheimer’s Disease Clinical Trials

11 **Phase 1 Trials in Alzheimer’s Disease Drug Development**   135  
Manfred Windisch

12 **The Importance of Phase 2 in Drug Development for Alzheimer’s Disease**   150  
Philip Scheltens, Willem de Haan, Roos J. Jutten, Everhard Vijverberg, Arno de Wilde, and Niels Prins

Contents

13	<b>Alzheimer's Disease Drug Development in Pharmaceutical Companies</b> 162	21	<b>The Role of Online Registries in Accelerating Alzheimer's Disease Drug Development</b> 257
	Eric Siemers, Robert A. Dean, James E. Senetar, Janice M. Hitchcock, and Russell L. Barton		Sarah Walter, Jessica Langbaum, and Rachel Nosheny
14	<b>Trial Site Infrastructure and Management: Importance to Alzheimer's Disease Drug Development</b> 170	22	<b>Data Safety Monitoring Boards in Alzheimer's Disease Trials</b> 266
	Marwan Sabbagh, Jiong Shi, Philip Scheltens, and Niels Prins		Emily D. Clark and Anton P. Porsteinsson
15	<b>ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development</b> 177	23	<b>Globalization of Alzheimer's Disease Clinical Trials</b> 275
	Paul S. Aisen, Rema Raman, Michael S. Rafii, Reisa A. Sperling, and Ronald C. Petersen		Huali Wang, Tao Wang, Shifu Xiao, and Xin Yu
16	<b>The European Prevention of Alzheimer's Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia</b> 190	24	<b>The Use and Development of Clinical Measures of Alzheimer's Disease Trials</b> 281
	Craig W. Ritchie, on behalf of the EPAD Consortium		John Harrison
17	<b>The Global Alzheimer's Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials</b> 207	25	<b>Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer's Disease Clinical Trials</b> 292
	Jason Bork, Cyndy Cordell, John Dwyer, Gabe Goldfeder, Debra R. Lappin, Richard Mohs, Julie Neild, Rona Schillinger, Jill Smith, Katy Smith, Leigh Zisko, and George Vradenburg		Rhoda Au, Honghuang Lin, and Vijaya B. Kolachalama
18	<b>Clinical Trial Development in Frontotemporal Lobar Degeneration</b> 216	26	<b>Expanded Access and Compassionate Use in Alzheimer's Disease Drug Development</b> 301
	Peter A. Ljubenkov and Adam Boxer		Diana Kerwin
19	<b>Statistical Considerations in the Design and Analysis of Alzheimer's Disease Clinical Trials</b> 232	27	<b>The Role of the Contract Research Organization in Alzheimer's Disease: The Vital Link in the Clinical Drug-Development Program</b> 309
	Suzanne B. Hendrix, Jessie Nicodemus-Johnson, Logan Kowallis, Newman Knowlton, Sean Hennessey, Samuel P. Dickson		John J. Sramek, Henry Riordan, Michael F. Murphy, and Neal R. Cutler
20	<b>Alzheimer's Disease Trial Recruitment and Diversifying Trial Populations</b> 249	28	<b>The Role of Regulatory Agencies in Alzheimer's Disease Drug Development</b> 319
	Samantha E. John		Cristina Sampaio and Swati Sathe
		29	<b>Alzheimer's Disease Clinical Trial Study Partners</b> 333
			Joshua Grill
		30	<b>From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?</b> 343
			Soeren Mattke

31 **Best Practices for Clinical Trials during COVID-19** 354  
Saif-Ur-Rahman Paracha, William Maurice Redden, and George Grossberg

Section 4: Imaging and Biomarker Development in Alzheimer's Disease Drug Discovery

32 **Development of Fluid Biomarkers for Alzheimer's Disease** 361  
Kaj Blennow

33 **Brain Imaging for Alzheimer's Disease Clinical Trials** 375  
Dawn C. Matthews and Mark E. Schmidt

34 **Sharing of Alzheimer's Disease Research Data in the Global Alzheimer's Association Interactive Network** 395  
Cally Xiao, Scott C. Neu, and Arthur W. Toga

35 **Pharmacogenetics in Alzheimer's Disease Drug Discovery and Personalized Treatment** 404  
Ramon Cacabelos

36 **The Role of Electroencephalography in Alzheimer's Disease Drug Development** 418  
Willem de Haan and Niels Prins

Section 5: Academic Drug-Development Programs

37 **Institutional Review Boards and Oversight of Alzheimer's Disease Trials** 429  
Emily A. Largent and Joshua Grill

38 **SPARKing Drug Development for Alzheimer's Disease in Academia** 437  
Daria Mochly-Rosen and Kevin V. Grimes

39 **The Role of Professional Associations and Patient Advocacy in Advancing**

**Alzheimer's Disease Drug Development** 449  
Amir Kalali and Gil Bashe

Section 6: Public–Private Partnerships in Alzheimer's Disease Drug Development

40 **Alzheimer's Disease Neuroimaging Initiative** 455  
Charles Bernick

Section 7: Funding and Financing Alzheimer's Disease Drug Development

41 **Financing Alzheimer's Disease Drug Development** 465  
Jayna Cummings, Amanda Hu, Angela Su, and Andrew W. Lo

42 **Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development** 480  
Lauren G. Friedman, Meriel Owen, Alessio Travaglia, and Howard Fillit

43 **Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development** 486  
Maria C. Carrillo, Emily A. S. Meyers, and Heather M. Snyder

44 **The Role of Philanthropy in Alzheimer's Disease Therapeutic Development** 496  
Cara Altimus

45 **National Institute on Aging's Alzheimer's Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer's Disease and Related Dementias** 503  
Laurie Ryan, Suzana Petanceska, and Lorenzo Refolo

Contents

46	<b>Alzheimer’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study</b>	513	48	<b>Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development</b>	533
	Susan Catalano			Pragati Katiyar, Armineh L. Ghazarian, Zane Martin, and Todd Haim	
47	<b>Introduction to Venture Capital in Alzheimer’s Disease Drug Development</b>	524			
	Laurence Barker, Jonathan Behr, and Christian Jung				

---

*Index* 544